<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01328522</url>
  </required_header>
  <id_info>
    <org_study_id>PKM12058</org_study_id>
    <secondary_id>U1111-1119-2883</secondary_id>
    <nct_id>NCT01328522</nct_id>
  </id_info>
  <brief_title>Comparison of the Safety and Pharmacokinetics of Two SAR153191 (REGN88) Drug Products in Rheumatoid Arthritis Patients</brief_title>
  <sponsors>
    <lead_sponsor>
      <agency>Sanofi</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Regeneron Pharmaceuticals</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Sanofi</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Primary Objective:&#xD;
&#xD;
      Assess the comparative safety and tolerability of two SAR153191 (REGN88) drug products after&#xD;
      a single dose administration in rheumatoid arthritis patients.&#xD;
&#xD;
      Secondary Objective:&#xD;
&#xD;
      Assess the comparative pharmacokinetic profiles of the two SAR153191 (REGN88) drug products&#xD;
      after a single dose administration in rheumatoid arthritis patients.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The duration of the study period per subject is 5-7 weeks broken down as follows:&#xD;
&#xD;
        -  Screening: 1 to 14 days,&#xD;
&#xD;
        -  Treatment: 1 day (2 overnight stays at the study site),&#xD;
&#xD;
        -  Follow-up: up to 5 weeks after dosing (an additional outpatient follow-up may be&#xD;
           scheduled depending on the last results).&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>May 2011</start_date>
  <completion_date type="Actual">September 2011</completion_date>
  <primary_completion_date type="Actual">September 2011</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Participant)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Occurrence of potentially clinically significant abnormalities in clinical laboratory test results</measure>
    <time_frame>5 weeks</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Occurrence of Adverse Events</measure>
    <time_frame>5 weeks</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Pain evaluation using the Present Pain Intensity (PPI) verbal questionnaire</measure>
    <time_frame>2 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pain evaluation using Visual Analog Scale (VAS)</measure>
    <time_frame>2 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Diameter of the erythema at injection site</measure>
    <time_frame>2 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Diameter of the edema at injection site</measure>
    <time_frame>2 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Serum concentration of SAR153191: Maximum plasma concentration (Cmax), first time to reach Cmax (tmax), area under the plasma concentration (AUClast and AUC)</measure>
    <time_frame>5 weeks</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">32</enrollment>
  <condition>Rheumatoid Arthritis</condition>
  <arm_group>
    <arm_group_label>SAR153191 drug product 1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>SAR153191 drug product 1 in a single injection.&#xD;
Methotrexate (stable dose) and folic/folinic acid are continued as background therapy.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>SAR153191 drug product 2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>SAR153191 drug product 2 in a single injection.&#xD;
Methotrexate (stable dose) and folic/folinic acid are continued as background therapy.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>SAR153191 (REGN88)</intervention_name>
    <description>Pharmaceutical form:solution&#xD;
Route of administration: subcutaneous</description>
    <arm_group_label>SAR153191 drug product 1</arm_group_label>
    <arm_group_label>SAR153191 drug product 2</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion criteria:&#xD;
&#xD;
          -  Diagnosis of rheumatoid arthritis (RA) &gt; or = 3 months duration.&#xD;
&#xD;
          -  Treated for a minimum of 12 weeks with Methotrexate (MTX) prior to randomization.&#xD;
             Treatment must be continued on a stable dose for the duration of the study.&#xD;
&#xD;
        Exclusion criteria:&#xD;
&#xD;
          -  Autoimmune disease other than RA.&#xD;
&#xD;
          -  History of acute inflammatory joint disease other than RA.&#xD;
&#xD;
          -  Surgery within 4 weeks prior to the screening visit or with planned elective surgery&#xD;
             within the next 3 months.&#xD;
&#xD;
          -  Latent or active tuberculosis.&#xD;
&#xD;
          -  Fever (â‰¥38 C) or persistent chronic or active recurring infection requiring treatment&#xD;
             with antibiotics, antivirals, or antifungals within 4 weeks prior to the screening&#xD;
             visit, or history of frequent recurrent infections.&#xD;
&#xD;
          -  Received administration of any live (attenuated) vaccine within 3 months prior to the&#xD;
             randomization visit (eg, varicella-zoster vaccine, oral polio, rabies).&#xD;
&#xD;
          -  Received tuberculosis vaccination within 12 months prior to screening&#xD;
&#xD;
          -  Prior therapy with a Tumor Necrosis Factor (TNF) antagonist or any other biologic&#xD;
             agents within 3 months prior to inclusion.&#xD;
&#xD;
          -  Known latex sensitivity.&#xD;
&#xD;
        The above information is not intended to contain all considerations relevant to a patient's&#xD;
        potential participation in a clinical trial.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Clinical Sciences &amp; Operations</last_name>
    <role>Study Director</role>
    <affiliation>Sanofi</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Investigational Site Number 840003</name>
      <address>
        <city>Beverly Hills</city>
        <state>California</state>
        <zip>90211</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 840001</name>
      <address>
        <city>Ocala</city>
        <state>Florida</state>
        <zip>34471</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 840004</name>
      <address>
        <city>Duncansville</city>
        <state>Pennsylvania</state>
        <zip>16635</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 840002</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>75235</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>October 2011</verification_date>
  <study_first_submitted>March 31, 2011</study_first_submitted>
  <study_first_submitted_qc>March 31, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 4, 2011</study_first_posted>
  <last_update_submitted>October 21, 2011</last_update_submitted>
  <last_update_submitted_qc>October 21, 2011</last_update_submitted_qc>
  <last_update_posted type="Estimate">October 24, 2011</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Arthritis</mesh_term>
    <mesh_term>Arthritis, Rheumatoid</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

